SOD1 ALS Pathway

SOD1 ALS Pathway

Introduction

Sod1 Als Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Mutations in the SOD1 gene (Superoxide Dismutase 1) were the first identified genetic cause of familial Amyotrophic Lateral Sclerosis (ALS), accounting for approximately 12-20% of familial ALS cases. Over 185 different SOD1 mutations have been identified, all causing ALS through a toxic gain-of-function mechanism rather than loss of enzymatic activity. [@novel]

Pathway Diagram

Molecular Mechanisms

1. Misfolding and Aggregation

SOD1 mutations cause protein misfolding through: [@btk]

• Destabilized dimer interface: Mutations weaken SOD1 dimer stability
• Reduced metal binding: Loss of zinc/copper cofactors increases aggregation
• Increased hydrophobic exposure: Promotes oligomerization and aggregation
• Post-translational modifications: Oxidation, nitration accelerate aggregation

The aggregation cascade: [@exploring]

Mutant SOD1 misfolds → 2. Oligomer formation → 3. Protofibrils → 4. Mature aggregates → 5. Inclusion bodies

2. Mitochondrial Dysfunction

Mutant SOD1 directly impairs mitochondria: [@impaired]

...

SOD1 ALS Pathway

Introduction

Sod1 Als Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

Mutations in the SOD1 gene (Superoxide Dismutase 1) were the first identified genetic cause of familial Amyotrophic Lateral Sclerosis (ALS), accounting for approximately 12-20% of familial ALS cases. Over 185 different SOD1 mutations have been identified, all causing ALS through a toxic gain-of-function mechanism rather than loss of enzymatic activity. [@novel]

Pathway Diagram

Molecular Mechanisms

1. Misfolding and Aggregation

SOD1 mutations cause protein misfolding through: [@btk]

• Destabilized dimer interface: Mutations weaken SOD1 dimer stability
• Reduced metal binding: Loss of zinc/copper cofactors increases aggregation
• Increased hydrophobic exposure: Promotes oligomerization and aggregation
• Post-translational modifications: Oxidation, nitration accelerate aggregation

The aggregation cascade: [@exploring]

Mutant SOD1 misfolds → 2. Oligomer formation → 3. Protofibrils → 4. Mature aggregates → 5. Inclusion bodies

2. Mitochondrial Dysfunction

Mutant SOD1 directly impairs mitochondria: [@impaired]

• Direct binding: Mutant SOD1 binds to mitochondria
• Complex I inhibition: Reduced ATP production
• Calcium handling: Impaired mitochondrial calcium buffering
• Drp1 dysregulation: Abnormal mitochondrial fission
• Apoptosis: Cytochrome c release, caspase activation

3. Oxidative Stress

While SOD1 normally protects against oxidative stress, mutant SOD1 paradoxically increases ROS: [^6]

• Aberrant peroxidase activity: Mutant SOD1 can use substrates improperly
• Nitric oxide interaction: Forms peroxynitrite
• Lipid peroxidation: Membrane damage
• DNA damage: 8-OHdG accumulation

4. Excitotoxicity

Motor neurons are particularly vulnerable to glutamate excitotoxicity: [^7]

• Reduced glutamate transport: EAAT2 downregulation
• AMPA receptor dysregulation: Calcium-permeable AMPA receptors
• Increased synaptic glutamate: Impaired reuptake
• mGluR1/5 activation: Group I metabotropic glutamate receptor involvement

5. Protein Homeostasis Disruption

Mutant SOD1 disrupts cellular protein quality control: [^8]

• Proteasome impairment: Direct inhibition by aggregates
• Autophagy dysfunction: Impaired autophagosome-lysosome fusion
• ER stress: Unfolded protein response activation
• Stress granules: Aberrant stress granule dynamics

Disease Associations

ALS Phenotype

• Age of onset: Typically 40-60 years
• Disease duration: 2-5 years (varies by mutation)
• Phenotype: Classic ALS with limb onset most common
• Penetrance: Near 100% by age 80

Mutation-Specific Features

| Mutation | Typical Phenotype | Notes | [^9]
|----------|-------------------|-------| [^10]
| A4V (most common US) | Rapid progression | Highly aggressive | [^11]
| G93A | Limb onset | Common in research models | [^12]
| G37R | Lower limb onset | Slower progression | [@nonnuclear2010]
| H46R | Bulbar onset | Japanese population | [^14]
| L126Z | Rapid progression | Truncated protein |

Interspecies Differences

• Transgenic mice: G93A, G37R, L126Z models extensively studied
• Zebrafish: Motor axonopathy models
• Drosophila: Genetic interaction studies

Therapeutic Implications

Approved Treatments

• Riluzole: Sodium channel blocker, reduces glutamate release
• Edaravone: Antioxidant, approved 2017

Clinical Trials

Gene silencing approaches

• ASO-mediated SOD1 knock-down
• AAV-delivered miRNA

Protein aggregation inhibitors

• Copper chelators
• Small molecule aggreg inhibitors

Mitochondrial protectors

• CoQ10 analogs
• Mitochondrial peptides

Neuroprotective agents

• Anti-excitotoxic compounds
• Autophagy enhancers

Biomarkers

• SOD1 activity: Reduced in mutation carriers
• Neurofilament light chain (NfL): Disease progression marker
• CSF total tau: Correlates with progression

Cross-Links

• [ALS Overview](/diseases/als)
• [TDP-43 Proteinopathy in ALS](/mechanisms/als-tdp43-pathology)
• [C9orf72 ALS Pathway](/mechanisms/als-c9orf72-pathway)
• [FUS ALS Pathway](/mechanisms/als-fus-pathway)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Stress](/mechanisms/oxidative-stress)

Background

The study of Sod1 Als Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology)
• [APP Processing](/mechanisms/app-processing)
• [Amyloid Aggregation](/mechanisms/amyloid-aggregation)
• [Tau Pathology](/mechanisms/tau-pathology)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [Structural Comparison of the Human G93A Mutant SOD1 to the Wild-type SOD1 Filaments.](https://pubmed.ncbi.nlm.nih.gov/41565003/) (2026 Mar 15) - Journal of molecular biology
• [Novel extracellular vesicle release pathway facilitated by toxic superoxide dismutase 1 oligomers.](https://pubmed.ncbi.nlm.nih.gov/41651252/) (2026 Mar) - Neurobiology of disease
• [BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis.](https://pubmed.ncbi.nlm.nih.gov/41710977/) (2026 Feb 19) - Brain : a journal of neurology
• [Exploring the ALS Multistep Model.](https://pubmed.ncbi.nlm.nih.gov/41750236/) (2026 Feb 18) - Brain sciences
• [Impaired nucleocytoplasmic transport in SOD1-mediated ALS.](https://pubmed.ncbi.nlm.nih.gov/41691309/) (2026 Feb 14) - Molecular neurodegeneration

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[@nonnuclear2010]: [^14]: Bosco DA, et al. (2010) Non-nuclear pathogenic pools of ALS-linked SOD1. Proc Natl Acad Sci U S A. 107(37):15969-15974.

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |

Overall Confidence: 47%

Additional Reading

SOD1 Aggregation Biochemistry

Structural Basis of Misfolding

SOD1 (Superoxide Dismutase 1) is a 154-amino acid homodimeric enzyme that catalyzes the dismutation of superoxide radicals. The wild-type protein has a highly stable structure:

• Dimer interface: Hydrophobic interactions between subunits
• Metal binding sites: One zinc site and one copper site per monomer
• Disulfide bond: Cys57-Cys146 stabilizes the structure
• Loop structures: Loops IV, V, and VI are flexible

Mutational Effects

ALS-associated mutations destabilize SOD1 through multiple mechanisms:

| Mutation Class | Examples | Effect |
|----------------|----------|--------|
| Dimer interface | G37R, G85R | Reduced dimer stability |
| Metal binding | H46R, H48R | Loss of metal cofactors |
| Disulfide bond | C146F | Structural destabilization |
| Hydrophobic core | A4V, L126Z | Exposed hydrophobic patches |
| Loop mutations | D90A | Altered folding kinetics |

Aggregation Kinetics

The aggregation process follows nucleation-dependent polymerization:

Monomer misfolding: Loss of native structure

Oligomer formation: Toxic intermediate species

Protofibril development: Early aggregate structures

Mature fibrils: Amyloid-like filaments

Inclusion body formation: Large cellular aggregates

SOD1 Toxicity Mechanisms

Prion-Like Propagation

SOD1 aggregates can spread between cells in a prion-like manner:

• Seeding: Exogenous SOD1 aggregates seed native protein misfolding
• Exosome release: Toxic oligomers released via extracellular vesicles
• Transfer across synapses: Inter-neuronal spread
• Template-directed misfolding: Native SOD1 conversion to pathological form

Axonal Transport Defects

Motor neurons are particularly vulnerable due to their reliance on axonal transport:

• Direct binding: Mutant SOD1 binds to transport machinery
• Mitochondrial obstruction: Aggregates block axonal transport
• vesicle trafficking: Impaired synaptic vesicle recycling
• Neurofilament compaction: Altered neurofilament organization

Non-Cell Autonomous Toxicity

Astrocyte-Mediated Effects

SOD1 mutation affects neighboring cells:

• Non-cell autonomous degeneration: Astrocytes expressing mutant SOD1 are toxic
• Impaired glutamate uptake: EAAT2 dysfunction in astrocytes
• Reduced trophic support: Decreased neurotrophic factor secretion
• Inflammatory activation: Pro-inflammatory cytokine release

Microglia Activation

The innate immune system contributes to progression:

• Chronic activation: Sustained microglial response
• NADPH oxidase activation: ROS production
• TREM2 signaling: Receptor for aggregated proteins
• Synaptic pruning: Enhanced elimination of motor neuron synapses

SOD1 Clinical Trials

Tofersen (BIIB067)

The first gene-silencing therapy for SOD1-ALS:

• Mechanism: Antisense oligonucleotide targeting SOD1 mRNA
• Administration: Intrathecal infusion
• Results: Reduced SOD1 protein in CSF, trend toward slower functional decline
• Status: Approved for SOD1-ALS (2023)

Other Approaches

| Approach | Target | Stage |
|----------|--------|-------|
| AAV-delivered miRNA | SOD1 | Preclinical |
| Small molecule stabilizers | SOD1 misfolding | Phase 1/2 |
| Copper chelators | Metal homeostasis | Phase 2 |
| Immunotherapies | SOD1 aggregates | Preclinical |

Biomarker Development in SOD1-ALS

Genetic Biomarkers

• Mutation type: Predicts disease progression rate
• Age of onset: Correlation with mutation position

Fluid Biomarkers

| Biomarker | Utility |
|-----------|---------|
| SOD1 in CSF | Target engagement for ASO therapy |
| NfL | Disease progression |
| pNfH | Axonal damage |
|NfL reduction after tofersen | Pharmacodynamic marker |

Imaging Biomarkers

• MRS: Metabolic changes in motor cortex
• DTI: White matter tract integrity
• PET: In development for SOD1 pathology

Experimental Models

Transgenic Mouse Models

| Model | Mutation | Features |
|-------|----------|----------|
| G93A-SOD1 | G93A | High expressor, rapid onset |
| G37R-SOD1 | G37R | Lower expression, slower onset |
| L126Z-SOD1 | L126Z | Truncated protein, aggressive |

iPSC Models

• Patient-derived motor neurons: Relevant cell type
• Isogenic controls: Mutation correction
• Age-related features: Maturation-dependent pathology

Mutation-Specific Phenotypes

Rapid Progression Mutations

• A4V: Median survival 1.2 years
• L126Z: Median survival 1.5 years
• G93A: Median survival 2-3 years

Slower Progression Mutations

• H46R: Median survival 5-7 years
• G37R: Median survival 5-8 years
• D90A: Median survival 7-10 years

Phenotype Variations

• Bulbar onset: More common with H46R
• Respiratory onset: G93A models show early diaphragmatic involvement
• Pure lower motor neuron: Some D90A carriers